Regeneus has filed 9 families of patent applications that if granted substantially as claimed cover the current products including HiQCell and CryoShot and a range of future products. The 9 patent families have been developed and are owned by the Company. The Company has licenced from Northern Sydney Local Health District exclusive rights to commercialise intellectually property rights relating to technology developed at the Kolling Institute of Medical Research for vaccines for the treatment or prevention of cancer in animals and humans. The patent applications have generally been, or will be when the time falls due, filed under the Patent Cooperation Treaty (PCT) that allows the making of the applications in most international territories.
All of our patents are being pursued worldwide. Regeneus holds the registered trademarks for HiQCell, CryoShot and AdiCell.